Dr Joanna Porter

Dr Joanna PorterTel: 020 3447 9004
Fax: 020 3447 9476
Email: UCLH.respiratorymedicine@nhs.net

Location:
University College Hospital

Specialities:
Respiratory Medicine

Professional background

Joanna Porter is a Consultant in Respiratory and General Medicine at UCLH and a HEFCE Senior Lecturer in the Department of Medicine at UCL. Joanna studied Medicine and Pharmacology at Cambridge University followed by clinical studies at Oxford University Medical School.  She went on to train in respiratory and intensive care medicine at the Brompton, St George's, and St Thomas'  hospitals, before completing her respiratory training at UCLH.  Joanna was awarded a PhD for her work in inflammation at UCL as an MRC Clinical Fellow and went on to be awarded a Wellcome Postdoctoral Clinical Fellowship at UCL.  Her clinical interest is in interstitial lung disease, in particular pulmonary fibrosis and interstitial lung disease in the context of autoimmune disorders.
 
Dr Porter sees patients on a Monday morning. Her clinic is JCP1A.

Research interests

  • Interstitial lung disease 
  • Idiopathic pulmonary fibrosis 
  • Rheumatological lung disease 
  • Autoimmune lung disease 
  • General respiratory medicine.   

Publications

1.  Porter JC, Hall, A.  Epithelial ICAM-1 and ICAM-2 regulate the egression of human T cells across the bronchial epithelium. FASEBJ. 2009: 23:492-502

2.  Porter JC, Falzon M, Hall A.  Polarized Localization Of Epithelial CXCL11 In Chronic Obstructive Pulmonary Disease and Mechanisms Of T-Cell Egression.  J. Immunol. 2008; 180:1866-1877 * rated by F1000 Medicine.

3.  Porter JC.  Transepithelial lymphocyte migration.  Methods in Enzymology 2008; 439:205-217

4.  Porter JC.  Dyspnea.  Comprehensive respiratory medicine 3rd Ed. Albert, R. K., Spiro, S. G., & Jett, J. R. (Eds.). (2008). * Mosby [Elsevier Science]

5.  Smith A, Bracke M, Leitinger B, Porter JC, Hogg N.  LFA-1 induced T cell adhesion to and migration on ICAM-1 involves compartmentalised regulation of MLCK-mediated attachment and ROCK-dependent detachment.
J. Cell Sci. 2003;116:3123-3133

6.  Porter JC, Bracke M. Smith A, Davies D and Hogg N.
Signaling through integrin LFA-1 leads to filamentous actin polymerization and remodeling, resulting in enhanced T cell adhesion. J. Immunol. 2002;168: 6330-6335

7.  Porter JC and Hogg N.   Integrin Cross-Talk: Activation of LFA-1 on human T cells alters α4β1- and α5β1-mediated function. J. Cell Biol. 1997;138 (6): 1437-1447.

Invited Editorials and Reviews

1.  Hogg N, Henderson R, Leitinger  B,  McDowall A, Porter  J,  Stanley P.  Mechanism contributing to the activity of integrins on leukocytes.Immunological Reviews. 2002; 186: 164-171

2.  Porter JC and Spiro SG.  Lung cancer--where are we today? Current advances in staging and nonsurgical treatment.  Am J Respir Crit Care Med. 2002;166(9):1166-96.

3.  Porter JC and Spiro SG.  Early detection of lung cancer.  Thorax 2000;55:S56-S62.

4.  Alexandroff AB, McIntyre C, Porter JC, Zeuthen J, Taub DD.Sticky and smelly issues: lessons on tumour cell and leucocyte trafficking, gene and immunotherapy of cancer.  Br. J. Cancer 1998;77 (11): 1806-1811

5.  Porter JC, Hogg N.Integrins take partners:  Cross-talk between integrins and other membrane receptors
Trends Cell Biol. 1998; 8: 390-396.

6.  Porter JC.  With Merlin in Rwanda.  Br. Med. J.  1995; 310:606

7.  Porter J, Ahsan A, Mulcachy D, Sigwart U. Coronary stents.  Br. J. Hosp. Med. 1992; 47:411-9.

8.  Porter JC, Tayler, EM, Thomas PBM, Templeton J.    Medical response to major disasters.   Injury 1990; 21:3

9.  Porter JC, Tayler EM, Thomas PBM.   Disaster planning.   Br. Med. J. 1989; 6675:755.

Publications as member of interleukin-1 receptor antagonist sepsis study group. 

1.  Recombinant human interleukin-1 receptor antagonist in the treatment of patients with sepsis syndrome.  Results from a randomised, double-blind, placebo-controlled trial.  Phase III rhIL-1ra sepsis syndrome study group.
JAMA 1994;271:1836-1843

2.  Use of predicted risk of mortality to evaluate the efficacy of anti-cytokine therapy in sepsis.  The rhIL-1ra phase III sepsis syndrome study group.
Crit. Care Med. 1996;24:46-56

3.  Confirmatory interleukin-1 receptor antagonist trial in severs sepsis: a phase III, randomized, double-blind, placebo-controlled multicenter trial.  The interleukin-1 receptor antagonist sepsis study group
Crit. Care Med. 1997; 25:1115-1124

Clinical Case Series, Reports and Letters

1.  Porter JC, Friedland JS, Ledingham JGG, Wojnarowska,F. 
Alveolitis associated with sulphamethoxypyridazine.    
Thorax 1989; 44:766-7.

2.  Porter J, Vesely M , Jane S, Stebbing A.   
Mesenteric vein thrombosis and protein S deficiency.   
Am. J. Gastroentrol. 1993; 88:2143.
 
3.  Roblin D, Porter JC, Knight RK.
Spontaneous migration of totally implanted venous catheter systems from subclavian into jugular veins. 
Thorax 1994; 3:281-282.

4.  Porter JC, Friedland JS, Freedman A. 
Tuberculous broncho-oesophageal fistulae: 3 case reports and a review of the literature.   
Clin. Infect. Dis. 1994; 19:954-7.

5.  Montgomery H, Porter JC, Bradley RD. 
Salicylate poisoning causing a severe systemic inflammatory response and rhabdomyolysis. 

6.  Am. J. Emerg. Med. 1994; 12(5):531-2.
Friedland JS & Porter JC 
Cytokine therapy in septic shock.   
N. Engl. J. Med. 1995; 333 (14):942

7.  Porter JC, Bennett ED, Friedland JS.
‘Further echoes of the Spanish lady’.
Lancet.  1996; 348:694.

GMC/GDC number: 3284432